Reported 26 days ago
Bristol Myers Squibb (BMY) has raised its full-year earnings guidance after exceeding third quarter expectations, resulting in a rise in its stock prices during pre-market trading. In contrast, Merck & Co. (MRK) has decreased its sales outlook despite beating third quarter estimates, which led to a decline in its stock value.
Source: YAHOO